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Abstract
The liver is the organ by which the majority of sub­
stances are metabolized, including psychotropic drugs. 
There are several pharmacokinetic changes in end­stage 
liver disease that can interfere with the metabolization 
of psychotropic drugs. This fact is particularly true 
in drugs with extensive first­pass metabolism, highly 
protein bound drugs and drugs depending on phase 
I hepatic metabolic reactions. Psychopharmacological 
agents are also associated with a risk of hepatotoxicity. 
The evidence is insufficient for definite conclusions 
regarding the prevalence and severity of psychiatric 
drug­induced liver injury. High­risk psychotropics are 
not advised when there is pre­existing liver disease, 
and after starting a psychotropic agent in a patient 
with hepatic impairment, frequent liver function/lesion 
monitoring is advised. The authors carefully review the 
pharmacokinetic disturbances induced by end­stage 
liver disease and the potential of psychopharmacological 
agents for liver toxicity.
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prevalence and severity of psychiatric drug­induced liver 
injury. High­risk psychotropics are not advised when 
there is pre­existing liver disease, and after starting a 
psychotropic agent in a patient with hepatic impairment, 
frequent liver function/lesion monitoring is advised.
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INTRODUCTION
Among all of the organs in the human body, the liver 
performs the greatest number of functions. The liver’s 
multiple activities are important and have impacts on all 
body systems, including the nervous system. It is also 
in the liver that most of the substances that we ingest 
are metabolized, including drugs. 
Liver failure occurs when large parts of the liver 
become damaged beyond repair, and the liver is no 
longer able to function. Drug-induced liver injury (DILI) 
is the 4th most important cause of liver disease in 
Western countries[1]. The incidence of DILI is between 
1/10000 and 1/100000 patients-years[2,3].
The drugs used in psychiatry and neurology are the 
second most important group of drugs implicated in 
hepatotoxicity, after anti-infectious drugs[4]. The hepatic 
reserve is reduced in patients with cirrhosis or chronic 
hepatic failure, and when DILI occurs in such patients, 
it can be more severe[5]. Therefore, high-risk drugs 
should be contraindicated in cases of pre-existing liver 
disease[6].
Conversely, liver failure interferes with different 
stages of drug pharmacokinetics: Absorption, meta-
bolism, distribution and elimination. Therefore, it affects 
drug concentrations, duration of action, and effective-
ness. It is essential to be aware of these processes and 
consequent changes in the circulating concentrations of 
psychiatric drugs to prevent drug toxicity. 
Psychiatric symptoms in patients with end-stage 
liver disease can occur due to co-existing psycholo-
gical or physiologic processes (e.g., liver failure, ence-
phalopathy, adjustment reactions to the stress of severe 
medical illness, etc.). All of these situations must be 
treated, not only with psychological interventions but 
also with psychotropic drugs. In these cases, patients 
with end-stage liver disease require special concern 
because they are medically vulnerable and are at 
increased risk for medication-induced adverse reactions. 
The purpose of this paper is to review the evidence 
regarding fundamental pharmacokinetic alterations 
caused by end stage liver disease as well as the 
potential for liver toxicity with psychopharmacological 
agents. In our review, we analyse the evidence for 
DILI, severe liver injury leading to death or liver trans-
plantation, abnormalities of liver function tests in 
clinical trials and hepatotoxicity. Finally, we provide 
several recommendations and directions regarding the 
psychotropic drugs that require special attention and 
how to minimize the risks of liver toxicity.
PHARMACOKINETIC CHANGES IN END-
STAGE LIVER DISEASE
Liver failure can affect some aspects of medication 
pharmacokinetics, ranging from absorption to distri-
bution and elimination. We discuss the most important 
pharmacokinetic processes that might lead to increased 
drug concentrations in liver disease patients.
Distribution
In end-stage liver disease, a great part of the blood in 
the portal vein escapes from the liver and flows straight 
into the systemic circulation (by means of portosystemic 
shunts). This process is due to intra- and extra-hepatic 
shunts that can occur in these patients. Therapeutic 
shunts (surgical and angiographic) can also be used to 
alleviate portal hypertension[7].
These shunts can affect first-pass metabolism by 
diminishing liver perfusion. In these cases, less drug 
passes through the liver before systemic distribu-
tion. Consequently, there is an elevation in drug con-
centrations in the blood. This effect is particularly 
important for drugs with extensive first-pass metabo-
lism (Table 1). The pharmacokinetics of other psycho-
tropic drugs, such as diazepam and paroxetine, with 
less affinity for liver enzymes, are not as influenced by 
first-pass metabolism[8].
Although olanzapine has great first-pass metabo-
lism, it is mostly metabolized by second-phase liver 
metabolic processes (preserved in liver disease), so 
it might not be an important factor for this particular 
drug[9].
Protein binding
More than 80% of psychiatric drugs are bound to plasma 
proteins, such as lipoproteins, alpha1-acid-glycoprotein 
and albumin. Some psychotropic drugs, such as fluo-
xetine, aripiprazole and diazepam, are highly protein 
bound. Nevertheless, there are some psychotropic drugs 
that minimally bind to proteins, such as venlafaxine, 
lithium, topiramate, gabapentin[10], pregabalin, methyl-
phenidate and memantine[11-17].
The cirrhotic liver produces a smaller quantity of 
albumin and alpha1-acid-glycoprotein, which is con-
ducive to an increased concentration of free active drug 
in the blood[18,19].
This increase is particularly important for highly 
protein-bound drugs, such as benzodiazepines (parti-
cularly diazepam, which is more than 99% protein 
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bound)[20]. Therefore, in cirrhosis, the side effects that 
result from the administration of these drugs, such as 
sedation, can be more severe. 
Metabolism
Some psychotropic drugs are water-soluble and are 
directly removed from the circulation in the urine and 
bile, which is the case with lithium, gabapentin, and 
topiramate[10]. However, all of the other psychotropic 
drugs are lipid soluble and must be metabolized in the 
liver, where they undergo some chemical changes and 
become more soluble. Only then can they be excreted 
in the urine or bile. 
The metabolic reactions that take place in the 
liver can occur in two main phases[19]. In phase I, 
cytochrome P-450 enzymes (monooxygenases) are 
responsible for the hydrolysis, oxidation, dealkylation 
or reduction of the molecule. Most of the time, these 
reactions decrease the pharmacological activity of the 
substrate. However, drugs are sometimes metabolized 
into active metabolites, which is the case with some 
benzodiazepines (such as diazepam, chlordiazepoxide), 
tricyclic antidepressants (such as amitriptyline and 
imipramine) and antipsychotics (such as chlorpromazine, 
thioridazine, risperidone)[10,21]. In phase II, liver enzymes 
are responsible for the conjugation of the drug with an 
endogenous molecule, such as glucuronic acid, sulphate, 
amino acids, acetate or glutathione. This process renders 
the original molecule more hydrophilic[19], and in most of 
the cases, it eliminates all of the pharmacological activity. 
Conjugation with glucuronic acid (glucuronidation) 
is normally preserved in liver disease[21]. Therefore, it 
might be beneficial to select a psychiatric drug that only 
requires glucuronidation (and does not require a phase I 
reaction), which is the case with temazepam, oxazepam, 
and lorazepam[8,9,19]. Olanzapine also requires almost 
only glucuronidation in its metabolization[9].
Fluid status
Although it is believed that water-soluble drugs, such as 
lithium, are safe to use in liver disease patients, there 
some aspects that must be considered.
In fact, it is not easy to maintain therapeutic serum 
levels of drugs such as lithium with the changes in 
fluid status that can occur in liver disease patients. 
These changes can be due to possibly abnormal renal 
haemodynamics (which often occur in liver disease 
patients) but also to any sudden change in fluid status 
that can occur due to some therapeutic procedures (such 
as paracentesis, extreme diuresis, or diarrhoea induced 
in the treatment of liver encephalopathy). 
If the total volume of body fluid is suddenly reduced, 
the regular therapeutic drug level can become critically 
toxic. Therefore, when using these types of drugs (such 
as lithium) in patients with cirrhosis, a strict coordination 
is mandatory between the different medical specialists 
that assist the patient[10,17].
DILI
DILI can be classified depending on different criteria: 
Underlying injury; pathophysiological mechanism; clini-
cal evolution; and severity of the lesion. Each of these 
criteria are reviewed.
Underlying liver injury
DILI can be classified into three main categories accord-
ing to the pattern of liver injury (i.e., hepatocellular and 
cholestatic or mixed). Hepatocellular injury accounts for 
90% of drug-induced hepatotoxicity and is associated 
with abnormally high serum alanine aminotransferase 
(ALT) titres, with a small or no increase in alkaline 
phosphatase (ALP) titres; an associated high serum 
bilirubin level, found in cases of severe hepatocellular 
damage, is a marker for poor prognosis[22]. Cholestatic 
liver injury is associated with high serum ALP titres only 
slightly higher than normal ALT levels; serum bilirubin 
concentrations might also be high. In cases of mixed 
injury, both ALT and ALP levels are abnormally high. 
Another type of lesion is steatosis. This reaction is 
generally chronic and occurs with gradual and increased 
fat accumulation in the liver (especially triglycerides), 
which can be caused by different situations, including 
the use of certain drugs. In drug-induced steatosis 
(almost always reversible), benign macrovacuolar 
steatosis can become steatohepatitis and cirrhosis in 
some cases[23].
Steatosis can occur with exposure to some antipsy-
chotics (e.g., clozapine, olanzapine) and antiepileptics 
(e.g., valproate)[23-28]. Less frequently, steatosis can be 
microvesicular, consistent with a more serious form of 
fat deposition in the hepatocytes, associated with more 
severe and acute clinical consequences (i.e., valproate or 
Reye’s syndrome). 
Pathophysiological types of DILI
Two pathophysiological types of DILI have been 
identified. 
The more common type is idiosyncratic, dose indepen-
dent and unpredictable[29]. It is the consequence either 
of immune-mediated liver damage (immunoallergic 
idiosyncratic DILI) or of direct cellular injury (metabolic 
idiosyncratic DILI)[30]. A hypersensitivity syndrome (fever, 
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  Tricyclic antidepressants - first-pass metabolism greater than 50% after 
  oral administration
  SNRI antidepressants - venlafaxine
  SSRI antidepressants - sertraline
  NRI antidepressants - bupropion
  Typical antipsychotics - chloropromazine 
  Atypical antipsychotics - olanzapine (40%), quetiapine
Table 1  Psychotropic drugs with extensive first-pass 
metabolism[10-16]
Telles­Correia D et al . Psychotropic drugs and liver disease
SSRI: Selective serotonin reuptake inhibitors; SNRI: Serotonin and nore-
pinephrine reuptake inhibitors; NRI: Norepinephrine reuptake inhibitors.
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patients treated and the short duration of the majority 
of clinical trials (6-12 wk) relative to the latency of 
DILI[36,37].
Antidepressants
Antidepressant-associated DILI is generally of the 
hepatocellular type and less frequently of the cholestatic 
or mixed type[31-34]. Concerning pathophysiology, it can 
be immunoallergic or metabolic. Various biological and 
clinical presentations are possible, ranging from isolated 
increases in liver enzyme levels to loss of hepatocellular 
function, acute liver failure, and death[38].
Based on severity and frequency of liver injuries 
reported for the different antidepressants, Voican 
classified the agents as high risk and lower risk. High-
risk agents include tricyclic antidepressants (imipramine, 
amitriptyline) and nefazodone (which has been with-
drawn from the market in several countries, due to 55 
severe cases of DILI reported, including 20 deaths), as 
well as venlafaxine, duloxetine, sertraline, bupropion, 
trazodone, and agomelatine[22,38-42].
Drugs with apparently lower risks are citalopram, 
escitalopram, paroxetine and fluvoxamine[38,43].
Gahr et al[44] confirmed the results of Voican’s com-
prehensive review using an innovative method. They 
calculated and compared reporting odds ratios, based 
on the number of adverse drug reactions related to 
hepatic disorders/total number of adverse drug reaction 
among several antidepressants[44].
Regarding agomelatine (AGM), there is disagreement 
between the pervasive idea that this antidepressant 
might have a great risk of liver toxicity and the availability 
of published data providing this evidence perhaps 
because of the short life of this antidepressant[44].
However, in a recent EMA (European Medicines 
Agency) post-authorization opinion, AGM was reported 
to be associated with a high hepatotoxic risk, and some 
limitations on its use were suggested. Clinical trials have 
shown a higher prevalence of increased ALT in patients 
treated with AGM (1.34% on AGM 25 mg/d, 2.51 on 
AGM 50 mg/d), compared to placebo (0.5%). Moreover, 
since the marketing authorization for AGM in 2009, 
several cases of severe liver injury-associated with AGM 
have been reported[6,30].
These cases indicate that AGM should be avoided 
in patients with pre-existing liver function compromise. 
Furthermore, it is recommended by the company res-
ponsible for this drug that regular laboratory analysis 
be performed in cases of prescription of AGM. If there is 
treatment-associated elevation of liver enzymes, AGM 
should be rapidly discontinued. Patients of female sex, 
who are older than 50 years of age, and who are poly-
medicated can have increased risk of liver toxicity related 
to AGM, although there is still only scarce regarding 
these matters. More studies are expected in this field, 
and they could likely affect the actual recommendations 
regarding AGM[6,44]. Table 2 summarizes the data on 
rash, eosinophilia, auto-antibodies) and a short latency 
period (1-6 wk)[30] suggest immune-mediated hepatic 
injury, whereas the absence of any hypersensitivity 
syndrome and a longer latency period (1 mo to 1 year) 
suggest an idiosyncratic metabolic mechanism[31]. 
Intrinsic DILI, related to drug accumulation, has also 
been described; it is dose dependent and predictable 
and has generally been observed during preclinical and 
clinical trials, leading to early drug withdrawal. 
Clinical evolution (acute/chronic)
DILI can be acute or chronic, depending on clinical 
presentation. Acute DILI is the most common form of 
DILI, accounting for 10% of all cases of acute hepatitis. 
Histologically, it can present as acute hepatitis, cho-
lestatic injury, a mixed pattern or acute steatosis. 
Chronic DILI is defined as persistence of abnormal liver 
enzymes for > 6 mo, and it accounts for 10% of DILI 
cases, more often following acute cholestasis. It can 
resemble other causes of chronic liver disease, such as 
autoimmune hepatitis or alcoholic liver disease[32].
Severity of DILI
Regarding its severity, DILI can be mild, severe and 
fatal.
According to the Drug-Induced Liver Injury Network 
(DILIN), in mild DILI, there is elevation of ALT and/or 
alkaline phosphatase, but no important increases in 
bilirubin and no impairment of coagulation. In severe 
DILI, there is elevation of ALT and/or alkaline pho-
sphatase, bilirubin is also increased, and one or more of 
the following exists: Extended jaundice for more than 
three months; and liver or other organ failure (induced 
by the drug). In fatal DILI, death occurs if the patient 
does not undergo liver transplantation[33].
The available data show that all psychotropic agents 
are associated with a risk of hepatotoxicity[34]. Most of 
the cases of DILI are mild, and liver tests normalize 
after drug withdrawal. Nevertheless, sometimes the 
consequences are very severe, leading to death or liver 
transplantation.
The most important means of assessing the poten-
tial for a psychotropic drug to cause severe or fatal 
hepatic injury is to review the published case reports. 
Nevertheless, there is no way to determine incidence 
rates, and the inexistence of case reports cannot be 
interpreted as the medication being free of risk regarding 
severe or fatal DILI. Conversely, the risks with different 
medications cannot be compared by this methodology 
because they are prescribed in different rates, and they 
have existed for different periods of time. For example, 
the probability of having case reports for older drugs is 
much higher than for newer ones[35].
Another problem is that, in many cases of reported 
DILI for a certain drug, the patient has co-medications 
and several medical co-morbidities.
Detection of DILI during premarketing clinical trials 
is a difficult challenge because of the small numbers of 
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The main mechanism by which chlorpromazine 
and other phenothiazines induce cholestatic disease 
remains unclear. The existence of eosinophilia and rash 
during its early onset (frequently 1 mo) and that there 
is not a dose relationship for its toxicity reveal that the 
mechanism could be some type of hypersensitivity. 
Nevertheless, some authors have indicated that its 
toxicity might be related to an idiosyncratic metabolic 
reaction that depends on individual sensitivity[2]. The bile 
duct can be the most affected, and as a consequence, a 
severe ductopenic syndrome can occur[2].
hepatotoxicity of the main antidepressant drugs. 
Antipsychotics
Cytochrome P450 (in the liver) is responsible for the 
metabolization of most antipsychotics (excluding 
sulpiride, amisulpride, and paliperidone)[97,98]. Antipsy-
chotics can induce liver injury by means of three main 
mechanisms: Hepatocellular, cholestatic and steatosis. 
Typical antipsychotics: The risk of hepatotoxicity with 
chlorpromazine is well established[34].
Epidemiology Type of lesion Mechanism
  Tricyclic antidepressants
     Imipramine ALT transient elevation-20%[45]
Cholestatic jaundice: 0.5%-1%[2]
DILI: 4/100000 patient-years[2,46] 
Fatal/Trxp DILI: 1[47]
Hepatocellular, cholestatic Immuno-allergic




     Clomipramine Severe DILI: 2 reports[42,49] Hepatocellular Immuno-allergic
  MAO inibitors
     Moclobemide Abnormal LFT: 3%[50]
Fatal DILI: 1[51]
Hepatocellular, cholestatic Immuno-allergic
  Serotonin-norepinephrine reuptake inhibitors
     Venlafaxine ALT > 3ULN: 0.4%[52]
Severe DILI: 6[53-56]
Fatal DILI/Trxp: 1[57]
Hepatocellular, cholestatic Immuno-allergic, metabolic
     Duloxetine ALT > 3ULN: 1.1%[58]




Hepatocellular, cholestatic, mixed Immuno-allergic, metabolic
  Serotonin-reuptake inhibitors




Hepatocellular, cholestatic, mixed Immuno-allergic, metabolic
     Paroxetine ALT > 3ULN: 1%[46]
Severe DILI: 4[68-71]
Hepatocellular, cholestatic, chronic hepatitis Metabolic
     Fluoxetine ALT > 3ULN: 0.5%[46]
Severe DILI: 6[72-77]
Hepatocellular, cholestatic, chronic hepatitis Metabolic
     Fluvoxamine Unknown[38]
DILI: 3[78-80]
Hepatocellular Metabolic
     Citalopram, escitalopram No difference in LFT vs placebo[81,82] ? ?
  Other antidepressants
     Nefazodone DILI: 28.96/10000 patient-years[38]
Severe DILI-35[83]
Fatal-20[83]
Hepatocellular, cholestatic, mixed Metabolic








     Agomelatine ALT > 3ULN: 1.4% (25 mg/d)
ALT > 3ULN: 2.5% (50 mg/d)[6,91]
Severe DILI: 6 reports[92,93]
Fatal/Trxp DILI: 1[94]
Hepatocellular
     Mirtazapine ALT > 3ULN: 2%[95]
Severe DILI 2: reports[96]
Table 2  Antidepressants and liver toxicity
DILI: Drug-induced liver injury; ALT: Alanine aminotransferase; LFT: Liver function tests; ULN: Upper normal limit.
Telles­Correia D et al . Psychotropic drugs and liver disease
31 February 6, 2017|Volume 8|Issue 1|WJGPT|www.wjgnet.com
be performed. Checking every year (and 6/6 mo in 
the case of clozapine) has been recommended[113]. In 
patients with heavy use of alcohol or other substances, 
more frequent control might be necessary. In this latter 
group of patients, it is also recommended to be more 
careful with slight changes in laboratory tests. If signs 
of liver compromise (e.g., jaundice, pruritus, nausea, 
anorexia, etc.) are present, laboratory tests should be 
assessed at once. 
The antipsychotic should be stopped if there is an 
asymptomatic increase in aminotransferases higher than 
3 times the maximum level of normal (aminotransferases 
are sensitive marker of liver injury)[114].
It is necessary to pay special attention to patients 
with pre-existing hepatic disease or patients treated 
with other drugs that can be aggressive to the liver. 
Because the majority of atypical antipsychotics are 
relatively new, there still are no long-term hepatic 
follow-ups with some of these drugs. Therefore, new 
evidence might appear in longer controlled studies 
regarding the frequency of and risk factors for liver 
damage[108].
In his comprehensive review, Marwick stated that LFT 
abnormalities in adults receiving regular antipsychotics 
are “common, early, mild, and often transient”[35]. 
Severe or fatal DILI is very rare. Chlorpromazine is the 
antipsychotic most associated with severe liver toxicity 
and therefore should not be used in patients with 
pre-existing liver dysfunction[35]. Among the atypical 
antipsychotics clozapine, is the antipsychotic most 
associated with LFT abnormalities, and aripiprazole, 
ziprasidone and amisulpride might be associated with 
A study that reviewed prescriptions in the United 
Kingdom between 1985 and 1991 showed a total 
incidence of chlorpromazine jaundice of 0.16% (more 
elevated in patients who were older than 70 years old, 
0.3%)[99].
Severe DILI was reported in more than 350 
cases[100,101], and fatal injury in 8 cases[102-109].
Haloperidol, while structurally similar to the pheno-
thiazines, rarely causes severe liver compromise. When 
it occurs, the mechanisms of liver toxicity are similar 
to those of phenothiazines (cholestatic lesions)[2]. A 
frequency of elevated liver enzymes of 2%[110] was 
reported, but only 1 case of severe DILI was reported[111].
Atypical antipsychotics: Atypical antipsychotics rarely 
induce severe liver toxicity. Nevertheless, asymptomatic 
increases in the levels of liver enzymes and bilirubin are 
not uncommon when using these psychotropic drugs. 
In most cases, the laboratory changes appear after 6 
wk of treatment, and they tend to disappear and not 
worsen[35].
The type of hepatic lesion associated with antipsy-
chotics can follow a primary hepatocellular pattern; 
therefore, the main change in laboratory tests seems 
to be an elevation in aminotransferases[35]. Nonalcoholic 
fatty liver disease can also be associated with treatment 
with atypical antipsychotics via metabolic syndrome, 
which they can induce[112].
Hence, many authors have advocated that it is 
important to assess liver function tests before initiating 
treatment with atypical antipsychotics, and subse-
quently, routine control of aminotransferases must 
Epidemiology Type of lesion Mechanism
  Typical
     Cloropromazine Jaundice: 0.16%-0.3%[99]
Severe DILI: > 350[100,101,115-124]
Fatal Injury: 8[102-109]
Cholestatic Immuno-allergic






























     Ziprasidone Not reported
Severe DILI: 1[167]
? ?
     Aripiprazole Not reported
     Amissulpride Not reported
Table 3  Antipsychotics and liver toxicity
DILI: Drug-induced liver injury; ALT: Alanine aminotransferase; ULN: Upper normal limit.
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Severe liver damage caused by carbamazepine is 
infrequent, but it has a very typical presentation. One to 
eight weeks after beginning treatment with this drug, a 
hypersensitivity syndrome occurs, with fever, rash, facial 
oedema, lymph node enlargement, and leucocytosis 
(with eosinophilia)[1,169].
Less frequently, carbamazepine-induced DILI can 
occur without immuno-allergic characteristics. In these 
cases, the resulting clinical syndrome has a late onset 
(up to 6 mo after initiating treatment)[1,169].
 Hypersensitivity is noted in up to 10% of patients. 
Hepatic adverse events have been reported to constitute 
10% of all hypersensitivity reactions, for a total inci-
dence of DILI due to carbamazepine hypersensitivity 
reactions of 1%[170].
Elevations in occur in less than 1% of patients on 
lamotrigine. Hepatotoxicity is rare and idiosyncratic, and 
it typically exhibits a hepatocellular pattern of injury[170]. 
The same outcome occurs with topiramate[1].
Benzodiazepine-induced liver damage is rare, with 
few cases reported in the literature, generally with a 
cholestatic pattern[171,172].
Long-term treatment with lithium can, in some 
cases, induce some LFT abnormalities. These changes 
are generally temporary and asymptomatic, reverting 
even if treatment continues. In cases of lithium over-
fewer LFT abnormalities. Table 3 summarizes the data 
about the hepatotoxicity of the main antipsychotics. 
Mood stabilizers and benzodiazepines
The overall incidence of the hepatotoxicity of antiepile-
ptics has been estimated at 1/26000 to 1/36000. The 
most used antiepileptic drugs in psychiatry are valproate, 
carbamazepine, topiramate, lamotrigine and gabapentin. 
Of these drugs, Valproate is associated with the greatest 
risk of potential liver toxicity. Gabapentin and pregabalin 
are the safest[129].
Valproate hepatotoxicity is generally idiosyncratic. 
The period of treatment before the onset of the 
injury can range from 3 d to 2 years. The absence of 
hypersensitivity symptoms, the morphology of the DILI 
and the slow onset suggest that the idiosyncrasy is 
metabolic. It is more common in infants and children[129].
Transient elevations of aminotransferases can be 
present in 10%-15% of patients and hyperbilirubinemia 
in up to 44%. Therapy can be continued as long the 
elevations in aminotransferases are less than 3 times 
the ULN. Sometimes, normalization of liver tests occurs 
likely because of adaptation[168]. Regarding carbama-
zepine, hepatic adverse events are frequent but are 
most represented by transient asymptomatic elevations 
in liver tests (ALT, AST, GGT).
Epidemiology Type of lesion Mechanism
  Antiepileptics






     Valproate Transient ALT, AST elevations: 10%-15% patients[170]
Hyperrubillirubinemia-44%[170]
DILI: 3%-44%[173] 
Fatal DILI: 0.02% (0.2% children < 2a)[1]
Hepatocellular Metabolic
(Toxic metabolites through 
w-oxidation)
Statosis








     Gabapentine; pregabaline Rare hepatotoxicity[1] ? ?
  Benzodiazepines
     Chlordiazepoxide, diazepam, flurazepam Rare hepatotoxicity[171,172] Cholestatic Hypersensitivity 
  Litium
Very rare hepatotoxicity[1] ? ?
Table 4  Mood stabilizers and benzodiazepines and liver toxicity
DILI: Drug-induced liver injury; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase.
  Avoid drugs with extensive first-pass metabolism Avoid Tricyclic Antidepressants (first-pass metabolism 50%), venlafaxine, sertraline, bupropion, 
chlorpromazine, quetiapine
  Avoid highly protein bound drugs Avoid most psychotropic drugs (specially fluoxetine, aripiprazole and benzodiazepines). Except: 
Venlafaxine, lithium, topiramate, a gabapentin, 
a pregabalin, memantine 
  Avoid drugs depending on phase I hepatic 
  metabolic reactions
Preferable: Lithium, gabapentin, topiramate, amisulpride (depending mainly on renal excretion)
and some benzodiazepines (oxazepam, temazepam, lorazepam) that depend on phase II reaction or 
glucuronidation, which is preserved in cirrhosis
Table 5  Pharmacokinetic changes caused by end-stage liver disease: Psychotropic drugs that require special attention
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to report these observations to their clinicians should 
they occur at any time after starting a psychotropic 
agent. Prompt discontinuation of the suspected agent 
at symptom onset might decrease the likelihood of 
worsening progression, which can lead to permanent 
liver damage[83].
REFERENCES
1 Schuster D, Laggner C, Langer T. Why drugs fail--a study on 
side effects in new chemical entities. Curr Pharm Des 2005; 11: 
3545-3559 [PMID: 16248807 DOI: 10.2174/138161205774414510]
2 Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. 
Hepatology 1999; 29: 1347-1351 [PMID: 10216114 DOI: 10.1002/
hep.510290535]
3 DeSanty KP, Amabile CM. Antidepressant-induced liver injury. 
Ann Pharmacother 2007; 41: 1201-1211 [PMID: 17609231 DOI: 
10.1345/aph.1K114]
4 Biour M, Salem CB, Chazouillères O, Grangé J-D, Serfati L, 
Poupon R. Hépatotoxicité des médicaments 14e mise à jour du 
fichier bibliographique des atteintes hépatiques et des médicaments 
responsables. Gastroentérologie Clinique et Biologique 2004; 28: 
720-59
5 Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky 
H, Saxena R, Kleiner D, Hoofnagle JH. Duloxetine hepatotoxicity: 
a case-series from the drug-induced liver injury network. Aliment 
Pharmacol Ther 2010; 32: 1174-1183 [PMID: 20815829 DOI: 
10.1111/j.1365-2036.2010.04449.x]
6 Gahr M, Freudenmann RW, Connemann BJ, Hiemke C, Schönfeldt-
Lecuona C. Agomelatine and hepatotoxicity: implications of 
cumulated data derived from spontaneous reports of adverse drug 
reactions. Pharmacopsychiatry 2013; 46: 214-220 [PMID: 23966266 
DOI: 10.1055/s-0033-1353156]
7 Powell DW. Approach to the patients with liver diseases. In: 
Goldman L, Bennett JC, editors. Cecil Textbook of Medicine. 21 
ed. Philadelphia: Saunders, 2000: 767-768
8 Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver 
disease. Pharmacol Ther 1989; 40: 439-474 [PMID: 2646653 DOI: 
10.1016/0163-7258(89)90088-0]
9 Withers N. The Liver-Impaired Patient. In: Leigh H, Streltzer J, 
editors. Handbook of Consultation Liason Psychiatry. New York: 
Springer, 2008: 248-269
10 Stevens J, Fava M, Rosenbaum J, Alpert J. Psychopharmacology in 
the medical setting. In: Stern T, Fricchione G, Cassem N, Jellinek M, 
Rosenbaum J, editors. Handbook of General Hospital Psychiatry. 6 
ed. Philadelphia: Saunders Elsevier, 2010
11 DeVane CL, Savett M, Jusko WJ. Desipramine and 2-hydroxy-
desipramine pharmacokinetics in normal volunteers. Eur J Clin 
Pharmacol 1981; 19: 61-64 [PMID: 7461025 DOI: 10.1007/
BF00558386]
12 Schroeder DH. Metabolism and kinetics of bupropion. J Clin 
Psychiatry 1983; 44: 79-81 [PMID: 6406469]
13 Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O. 
Seroquel (ICI 204 636), a putative “atypical” antipsychotic, in 
schizophrenia with positive symptomatology: results of an open 
clinical trial and changes of neuroendocrinological and EEG 
parameters. Psychopharmacology (Berl) 1995; 119: 231-238 
[PMID: 7659771 DOI: 10.1007/BF02246165]
14 Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko 
WJ, Chiang ST. Introduction of a composite parameter to the 
pharmacokinetics of venlafaxine and its active O-desmethyl 
metabolite. J Clin Pharmacol 1992; 32: 716-724 [PMID: 1487561 
DOI: 10.1002/j.1552-4604.1992.tb03875.x]
15 Troy SM, Parker VP, Hicks DR, Pollack GM, Chiang ST. 
Pharmacokinetics and effect of food on the bioavailability of orally 
administered venlafaxine. J Clin Pharmacol 1997; 37: 954-961 
[PMID: 9505987 DOI: 10.1002/j.1552-4604.1997.tb04270.x]
16 Mandrioli R, Mercolini L, Raggi MA. Evaluation of the 
dose, these LFT changes can be marked, although the 
damage is much more severe in other organs, such 
as the kidney[1]. Table 4 summarizes the data about 
the hepatotoxicity of the main mood stabilizers and 
benzodiazepines. 
CONCLUSION AND GENERAL 
RECOMMENDATIONS
The available data on psychotropic drug-induced 
hepatic toxicity are mostly from reported cases and, 
to a lesser extent, from the results of clinical trials and 
other studies, especially for the most recent drugs. 
It is therefore difficult to draw conclusions about the 
prevalence and severity of DILI. 
Regarding pharmacokinetic changes in end-stage 
liver disease, there are some psychotropic drugs that 
require special attention, as shown in Table 5.
It is likely that all psychopharmacological agents are 
associated with a risk of hepatotoxicity. However, the 
evidence is insufficient for rigorous conclusions to be 
drawn about the prevalence and severity of psychiatric 
DILI[175].
Hepatic reserve is reduced in patients with cirrhosis 
or chronic hepatic failure, and when DILI occurs in such 
patients, it can be more severe[5,176]. Therefore, high-risk 
drugs should be contraindicated in cases of pre-existing 
liver disease[6] (based on comprehensive reviews). 
Before starting a psychotropic agent, baseline la-
boratory testing (e.g., LFT, ALT) is recommended[113,177]. 
If liver disease is present, it is preferable to use psycho-
tropic drugs with minimal liver metabolism (e.g., 
topiramate, sulpiride and amisulpride)[35]. High-risk psy-
chotropic agents (referred to in comprehensive reviews, 
see above) are not advised when there is pre-existing 
liver disease. After starting a psychotropic agent in a 
patient with hepatic impairment, frequent liver function/
lesion monitoring is advised[113].
If a patient has normal laboratory tests (e.g., LFT, 
ALT) before initiating treatment, there is no clear unani-
mity regarding the frequency of analysis re-assess-
ment. Laboratory tests with ALT > 3ULN or ALP > 2ULN 
are considered sensitive markers for liver damage, 
and in these cases, the psychotropic agent should be 
stopped[35,114].
After starting a psychotropic agent, patients should 
be counselled to report signs and symptoms of liver 
dysfunction that could be associated with the use of 
their drug, including weight loss/decreased appetite, 
gastrointestinal problems or changes, dark (i.e., tea-
coloured) urine, yellowing of eyes (i.e., jaundice), 
weakness, or unexplained/increasing fatigue. Other 
signs and symptoms include pruritus, clay-coloured 
stools, muscle pain, and increased confusion. Some of 
these conditions are already associated with chronic 
hepatitis infection, so it is important to emphasize 
observations of new-onset signs and symptoms. 
Patients and/or their caretakers should be encouraged 
Telles­Correia D et al . Psychotropic drugs and liver disease
34 February 6, 2017|Volume 8|Issue 1|WJGPT|www.wjgnet.com
Elsevier, 2009
35 Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal 
liver function tests: systematic review. Clin Neuropharmacol 
2012; 35: 244-253 [PMID: 22986798 DOI: 10.1097/WNF.0b013e-
31826818b6]
36 Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman 
RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, 
Rush AJ, Hirschfeld RM, LaVange LM, Keller MB. Sertraline 
versus imipramine to prevent relapse in chronic depression. J Affect 
Disord 2001; 65: 27-36 [PMID: 11426506 DOI: 10.1016/S0165-
0327(00)00272-X]
37 Van Amerongen AP, Ferrey G, Tournoux A. A randomised, double-
blind comparison of milnacipran and imipramine in the treatment of 
depression. J Affect Disord 2002; 72: 21-31 [PMID: 12204314 DOI: 
10.1016/S0165-0327(01)00422-0]
38 Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-
induced liver injury: a review for clinicians. Am J Psychiatry 
2014; 171: 404-415 [PMID: 24362450 DOI: 10.1176/appi.ajp.2-
013.13050709]
39 Randeva HS, Bangar V, Sailesh S, Hillhouse EW. Fatal cholestatic 
jaundice associated with amitriptyline. Int J Clin Pract 2000; 54: 
405-406 [PMID: 11092117]
40 Conway CR, McGuire JM, Baram VY. Nefazodone-induced 
liver failure. J Clin Psychopharmacol 2004; 24: 353-354 [PMID: 
15118496]
41 Medicines and Healthcare products Regulatory Agency. Ago-
melatine (Valdoxan): risk of liver toxicity. Drug Safety Update, 
2014; 8(4). Available from: URL: https://www.gov.uk/drug-safety-
update/agomelatine-valdoxan-risk-of-liver-toxicity
42 Atmaca M. Acute Severe Hepatotoxicity Associated with Clomi-
pramine. Klin Psikofarmakol B 2011; 21: 154-5 [DOI: 10.5455/
bcp.20110706030609]
43 Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin 
Psychiatry 1992; 53 Suppl: 61-66 [PMID: 1531828]
44 Gahr M, Zeiss R, Lang D, Connemann BJ, Schönfeldt-Lecuona C. 
Hepatotoxicity associated with agomelatine and other antidepressants: 
Disproportionality analysis using pooled pharmacovigilance data from 
the Uppsala Monitoring Centre. J Clin Pharmacol 2015; 55: 768-773 
[PMID: 25650773 DOI: 10.1002/jcph.475]
45 Kaplowitz N. Drug-Induced Liver Injury: Introduction and 
Overview. In: Kaplowitz N, DeLeve L, editors. Drug-Induced Liver 
Disease. 3rd ed. San Diego, USA: Elsevier, 2013
46 Carvajal García-Pando A, García del Pozo J, Sánchez AS, Velasco 
MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated 
with the new antidepressants. J Clin Psychiatry 2002; 63: 135-137 
[PMID: 11874214 DOI: 10.4088/JCP.v63n0208]
47 Powell WJ, Koch-Weser J, Williams RA. Lethal hepatic necrosis 
after therapy with imipramine and desipramine. JAMA 1968; 206: 
642-645 [PMID: 4234079 DOI: 10.1001/jama.206.3.642]
48 Holmberg MB. A study of blood count and serum transaminase 
in prolonged treatment with amitriptyline. J New Drugs 1962; 2: 
361-365 [PMID: 13961401 DOI: 10.1177/009127006200200606]
49 Alderman CP, Atchison MM, McNeece JI. Concurrent agranu-
locytosis and hepatitis secondary to clomipramine therapy. Br J 
Psychiatry 1993; 162: 688-689 [PMID: 8149124 DOI: 10.1192/
bjp.162.5.688]
50 Zimmerman HJ, Ishak KG. The hepatic injury of monoamine 
oxidase inhibitors. J Clin Psychopharmacol 1987; 7: 211-213 
[PMID: 3624504]
51 Timmings P, Lamont D. Intrahepatic cholestasis associated with 
moclobemide leading to death. Lancet 1996; 347: 762-763 [PMID: 
8602021 DOI: 10.1016/S0140-6736(96)90114-2]
52 Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine 
hydrochloride: analysis of the clinical trials database. J Clin 
Psychopharmacol 1996; 16: 54S-59S; discussion 59S-61S [PMID: 
8784648 DOI: 10.1097/00004714-199606002-00011]
53 Sencan I, Sahin I, Ozcetin A. Low-dose venlafaxine-associated 
liver toxicity in chronic hepatitis. Ann Pharmacother 2004; 38: 
352-353 [PMID: 14742779 DOI: 10.1345/aph.1D205]
54 Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated 
pharmacokinetics, safety and clinical efficacy of sertraline used to treat 
social anxiety. Expert Opin Drug Metab Toxicol 2013; 9: 1495-1505 
[PMID: 23834458 DOI: 10.1517/17425255.2013.816675]
17 Crone CC, Gabriel GM, DiMartini A. An overview of psychiatric 
issues in liver disease for the consultation-liaison psychiatrist. 
Psychosomatics 2006; 47: 188-205 [PMID: 16684936 DOI: 
10.1176/appi.psy.47.3.188]
18 Blaschke TF. Protein binding and kinetics of drugs in liver 
diseases. Clin Pharmacokinet 1977; 2: 32-44 [PMID: 322909 DOI: 
10.2165/00003088-197702010-00003]
19 Adedoyin A, Branch RA. Pharmacokinetics. In: Zakim D, Boyer 
TD, editors. Hepatology: A Textbook of Liver Disease. 3 ed. 
Philadelphia: Saunders Elsevier, 1996
20 Doweiko H. Concepts of Chemical Dependency. 8 ed. Belmont: 
Brooks/Cole, 2009
21 Beers MH, Berkow R. The Merck Manual of Diagnosis and 
Therapy. 17 ed. West Point, PA: Merck and Co, Inc, 1999
22 Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, 
Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson 
E, Daly AK. Case definition and phenotype standardization in drug-
induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815 [PMID: 
21544079 DOI: 10.1038/clpt.2011.58]
23 Zhang X, Ouyang J, Thung S. Histopathologic Manifestations of 
Drug-induced Hepatotoxicity. In: Pyrsopoulos N, editor. Clinics 
Review Articles: Drug Hepatotoxicity. Philadelphia: Elsevier, 2013: 
547-559
24 Donato MT, Gómez-Lechón MJ. Drug-induced liver steatosis 
and phospholipidosis: cell-based assays for early screening of 
drug candidates. Curr Drug Metab 2012; 13: 1160-1173 [PMID: 
22746303 DOI: 10.2174/138920012802850001]
25 Zhang WV, Ramzan I, Murray M. Impaired microsomal oxidation 
of the atypical antipsychotic agent clozapine in hepatic steatosis. J 
Pharmacol Exp Ther 2007; 322: 770-777 [PMID: 17522342 DOI: 
10.1124/jpet.107.124024]
26 Soliman HM, Wagih HM, Algaidi SA, Hafiz AH. Histological 
evaluation of the role of atypical antipsychotic drugs in inducing 
non-alcoholic fatty liver disease in adult male albino rats (light and 
electron microscopic study). Folia Biol (Praha) 2013; 59: 173-180 
[PMID: 24280139]
27 Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky 
HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, 
Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH. Hepatic 
histological findings in suspected drug-induced liver injury: 
systematic evaluation and clinical associations. Hepatology 2014; 
59: 661-670 [PMID: 24037963 DOI: 10.1002/hep.26709]
28 Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin 
Liver Dis 2014; 34: 205-214 [PMID: 24879984 DOI: 10.1055/
s-0034-1375960]
29 Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, 
Chalasani N. Relationship between daily dose of oral medications 
and idiosyncratic drug-induced liver injury: search for signals. 
Hepatology 2008; 47: 2003-2009 [PMID: 18454504 DOI: 10.1002/
hep.22272]
30 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug 
Discov 2005; 4: 489-499 [PMID: 15931258 DOI: 10.1038/nrd1750]
31 Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, 
García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, 
Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, 
Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R. 
Drug-induced liver injury: an analysis of 461 incidences submitted to 
the Spanish registry over a 10-year period. Gastroenterology 2005; 
129: 512-21
32 Mark D, Harbord M. Emergencies in Gastroenterology and 
Hepatology. Oxford: Oxford University Press, 2013
33 Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano 
J, Hoofnagle JH. Standardization of nomenclature and causality 
assessment in drug-induced liver injury: summary of a clinical 
research workshop. Hepatology 2010; 52: 730-742 [PMID: 
20564754 DOI: 10.1002/hep.23696]
34 Aronson JK. Meyler’s Side Effects of Psychiatric Drugs. Oxford: 
Telles­Correia D et al . Psychotropic drugs and liver disease
35 February 6, 2017|Volume 8|Issue 1|WJGPT|www.wjgnet.com
73 Friedenberg FK, Rothstein KD. Hepatitis secondary to fluoxetine 
treatment. Am J Psychiatry 1996; 153: 580 [PMID: 8599417 DOI: 
10.1176/ajp.153.4.580a]
74 Johnston DE, Wheeler DE. Chronic hepatitis related to use of 
fluoxetine. Am J Gastroenterol 1997; 92: 1225-1226 [PMID: 
9219808]
75 Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, 
Kirchner JP. Acute hepatitis due to fluoxetine therapy. Mayo Clin 
Proc 1999; 74: 692-694 [PMID: 10405699 DOI: 10.4065/74.7.692]
76 Shuster J. Fluoxetine and hepatitis. Nursing 2000; 30: 78 [PMID: 
11249443]
77 Capellà D, Bruguera M, Figueras A, Laporte J. Fluoxetine-induced 
hepatitis: why is postmarketing surveillance needed? Eur J Clin 
Pharmacol 1999; 55: 545-546 [PMID: 10501826 DOI: 10.1007/
s002280050671]
78 Solomons K, Gooch S, Wong A. Toxicity with selective serotonin 
reuptake inhibitors. Am J Psychiatry 2005; 162: 1225 [PMID: 
15930079 DOI: 10.1176/appi.ajp.162.6.1225]
79 Bamrah JS, Benbow SM, McKenna J. Fluvoxamine and liver 
enzymes. Br J Psychiatry 1990; 156: 286-287 [PMID: 2107955 
DOI: 10.1192/bjp.156.2.286b]
80 Green BH. Fluvoxamine and hepatic function. Br J Psychiatry 
1988; 153: 130-131 [PMID: 2906264 DOI: 10.1192/bjp.153.1.130]
81 Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label 
trial of citalopram for major depression in patients with hepatitis C. 
J Clin Psychiatry 2002; 63: 194-198 [PMID: 11926717]
82 Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, 
Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, 
Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz 
A, Discher T, Neumann K, Zeuzem S, Berg T. Escitalopram for the 
prevention of peginterferon-α2a-associated depression in hepatitis 
C virus-infected patients without previous psychiatric disease: 
a randomized trial. Ann Intern Med 2012; 157: 94-103 [PMID: 
22801672 DOI: 10.7326/0003-4819-157-2-201207170-00006]
83 Park SH, Ishino R. Liver injury associated with antidepressants. 
Curr Drug Saf 2013; 8: 207-223 [PMID: 23914755 DOI: 10.2174/1
574886311308030011]
84 Rettman KS, McClintock C. Hepatotoxicity after short-term 
trazodone therapy. Ann Pharmacother 2001; 35: 1559-1561 [PMID: 
11793619]
85 Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated 
with trazodone and neuroleptic drugs. BMJ 1994; 309: 378 [PMID: 
7915924 DOI: 10.1136/bmj.309.6951.378]
86 Hu KQ, Tiyyagura L, Kanel G, Redeker AG. Acute hepatitis 
induced by bupropion. Dig Dis Sci 2000; 45: 1872-1873 [PMID: 
11052334]
87 Alonso Rodríguez L, Barcina Pajares R, Fuentes Vigil J, Gutiérrez 
González A, Rodríguez Pérez L. Acute toxic hepatitis secondary 
to a single dose of bupropion. Gastroenterol Hepatol 2010; 33: 
547-549 [PMID: 20435378 DOI: 10.1016/j.gastrohep.2010.02.009]
88 Alvaro D, Onetti-Muda A, Moscatelli R, Atili AF. Acute cholestatic 
hepatitis induced by bupropion prescribed as pharmacological 
support to stop smoking. A case report. Dig Liver Dis 2001; 33: 
703-706 [PMID: 11785718 DOI: 10.1016/S1590-8658(01)80049-9]
89 Khoo AL, Tham LS, Lee KH, Lim GK. Acute liver failure with 
concurrent bupropion and carbimazole therapy. Ann Pharmacother 
2003; 37: 220-223 [PMID: 12549952 DOI: 10.1345/aph.1C159]
90 Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case 
of bupropion (Zyban) hepatotoxicity with autoimmune features: 
Case report. J Med Case Rep 2007; 1: 88 [PMID: 17877816 DOI: 
10.1186/1752-1947-1-88]
91 Howland RH. A benefit-risk assessment of agomelatine in the 
treatment of major depression. Drug Saf 2011; 34: 709-731 [PMID: 
21830835 DOI: 10.2165/11593960-000000000-00000]
92 Montastruc F, Scotto S, Vaz IR, Guerra LN, Escudero A, Sáinz M, 
Falomir T, Bagheri H, Herdeiro MT, Venegoni M, Montastruc JL, 
Carvajal A. Hepatotoxicity related to agomelatine and other new 
antidepressants: a case/noncase approach with information from 
the Portuguese, French, Spanish, and Italian pharmacovigilance 
systems. J Clin Psychopharmacol 2014; 34: 327-330 [PMID: 
hepatitis. Ann Intern Med 1999; 130: 944 [PMID: 10375350 DOI: 
10.7326/0003-4819-130-11-199906010-00014]
55 Cardona X, Avila A, Castellanos P. Venlafaxine-associated 
hepatitis. Ann Intern Med 2000; 132: 417 [PMID: 10691596 DOI: 
10.7326/0003-4819-132-5-200003070-00016]
56 Yildirim B, Tuncer C, Ergun M, Unal S. Venlafaxine-induced 
hepatotoxicity in a patient with ulcerative colitis. Ann Hepatol 
2009; 8: 271-272 [PMID: 19841512]
57 Detry O, Delwaide J, De Roover A, Hans MF, Delbouille MH, 
Monard J, Honoré P. Fulminant hepatic failure induced by venlafaxine 
and trazodone therapy: a case report. Transplant Proc 2009; 41: 
3435-3436 [PMID: 19857765 DOI: 10.1016/j.transproceed.2009.09.0
22]
58 Xue F, Strombom I, Turnbull B, Zhu S, Seeger JD. Duloxetine 
for depression and the incidence of hepatic events in adults. J Clin 
Psychopharmacol 2011; 31: 517-522 [PMID: 21694615 DOI: 
10.1097/JCP.0b013e31822347d9]
59 Choy EH, Mease PJ, Kajdasz DK, Wohlreich MM, Crits-Christoph 
P, Walker DJ, Chappell AS. Safety and tolerability of duloxetine 
in the treatment of patients with fibromyalgia: pooled analysis of 
data from five clinical trials. Clin Rheumatol 2009; 28: 1035-1044 
[PMID: 19533210 DOI: 10.1007/s10067-009-1203-2]
60 McIntyre RS, Panjwani ZD, Nguyen HT, Woldeyohannes HO, 
Alsuwaidan M, Soczynska JK, Lourenco MT, Konarski JZ, Kennedy 
SH. The hepatic safety profile of duloxetine: a review. Expert Opin 
Drug Metab Toxicol 2008; 4: 281-285 [PMID: 18363543 DOI: 10.151
7/17425255.4.3.281]
61 Wernicke J, Acharya N, Strombom I, Gahimer JL, D’Souza DN, 
DiPietro N, Uetrecht JP. Hepatic effects of duloxetine-II: spontaneous 
reports and epidemiology of hepatic events. Curr Drug Saf 2008; 3: 
143-153 [PMID: 18690992 DOI: 10.2174/157488608784529198]
62 Hautekeete ML, Colle I, van Vlierberghe H, Elewaut A. Symptomatic 
liver injury probably related to sertraline. Gastroenterol Clin Biol 
1998; 22: 364-365 [PMID: 9762229]
63 Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and 
review of the literature on selective serotonin reuptake inhibitor 
hepatotoxicity. Dig Dis Sci 2003; 48: 939-944 [PMID: 12772794]
64 Tabak F, Gunduz F, Tahan V, Tabak O, Ozaras R. Sertraline 
hepatotoxicity: report of a case and review of the literature. Dig 
Dis Sci 2009; 54: 1589-1591 [PMID: 18958618 DOI: 10.1007/
s10620-008-0524-3]
65 Menon RR, Howard R. Sertraline and liver toxicity in the elderly 
(letter). Int J Geriatr Psychiatr 1994; 9: 332-4 [DOI: 10.1002/
gps.930090411]
66 Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis 
possibly associated with donepezil and sertraline therapy. J Am 
Geriatr Soc 2000; 48: 1659-1663 [PMID: 11129758 DOI: 10.1111/
j.1532-5415.2000.tb03879.x]
67 Fartoux-Heymann L, Hézode C, Zafrani ES, Dhumeaux D, Mallat 
A. Acute fatal hepatitis related to sertraline. J Hepatol 2001; 35: 
683-684 [PMID: 11690719 DOI: 10.1016/S0168-8278(01)00159-3]
68 Cadranel JF, Di Martino V, Cazier A, Pras V, Bachmeyer C, 
Olympio P, Gonzenbach A, Mofredj A, Coutarel P, Devergie B, 
Biour M. Atrium and paroxetine-related severe hepatitis. J Clin 
Gastroenterol 1999; 28: 52-55 [PMID: 9916669 DOI: 10.1097/000
04836-199901000-00014]
69 Odeh M, Misselevech I, Boss JH, Oliven A. Severe hepatotoxicity 
with jaundice associated with paroxetine. Am J Gastroenterol 
2001; 96: 2494-2496 [PMID: 11513198 DOI: 10.1111/j.1572-
0241.2001.04060.x]
70 Colakoglu O, Tankurt E, Unsal B, Ugur F, Kupelioglu A, Buyrac 
Z, Akpinar Z. Toxic hepatitis associated with paroxetine. Int J 
Clin Pract 2005; 59: 861-862 [PMID: 15963219 DOI: 10.1111/
j.1368-5031.2005.00572.x]
71 Pompili M, Tittoto P, Mascianà R, Gasbarrini G, Rapaccini GL. Acute 
hepatitis associated with use of paroxetine. Intern Emerg Med 2008; 3: 
275-277 [PMID: 18265937 DOI: 10.1007/s11739-008-0111-9]
72 Cosme A, Barrio J, Lobo C, Gil I, Castiella A, Arenas JI. Acute 
cholestasis by fluoxetine. Am J Gastroenterol 1996; 91: 2449-2450 
[PMID: 8931446]
Telles­Correia D et al . Psychotropic drugs and liver disease
36 February 6, 2017|Volume 8|Issue 1|WJGPT|www.wjgnet.com
of drug-induced liver injury. Gut 2009; 58: 1555-1564 [PMID: 
19834119 DOI: 10.1136/gut.2008.163675]
115 Ben-Yehuda A, Bloom A, Lijovetzky G, Flusser D, Tur-Kaspa 
R. Chlorpromazine-induced liver and bone marrow granulomas 
associated with agranulocytosis. Isr J Med Sci 1990; 26: 449-451 
[PMID: 2401609]
116 Bolton BH. Prolonged chlorpromazine jaundice. Am J Gastroenterol 
1967; 48: 497-503 [PMID: 5583132]
117 Cheongvee EM, Hurst L, Smith RH. Agranulocytosis and jaundice 
associated with chlorpromazine. Br J Clin Pract 1967; 21: 95-96 
[PMID: 6037940]
118 Chlumská A, Curík R, Boudová L, Mukensnabl P, Klvana P. 
Chlorpromazine-induced cholestatic liver disease with ductopenia. 
Cesk Patol 2001; 37: 118-122 [PMID: 11669021]
119 Johnson EI, Lanford RE, Solomon K. Chlorpromazine, eosino-
philia, and hepatotoxicity. Va Med 1979; 106: 683-684 [PMID: 
484004]
120 Levine RA, Briggs GW, Lowell DM. Chronic chlorpromazine 
cholangiolitic hepatitis. Report of a case with immunofluorescent 
studies. Gastroenterology 1966; 50: 665-670 [PMID: 5327471 DOI: 
10.1016/S0016-5085(66)80126-9]
121 Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger 
C, Jost R, Schmid M. Chlorpromazine-induced vanishing bile 
duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20: 
1437-1441 [PMID: 7982642 DOI: 10.1002/hep.1840200610]
122 Russell RI, Allan JG, Patrick R. Active chronic hepatitis after chlor-
promazine ingestion. Br Med J 1973; 1: 655-656 [PMID: 4692711 
DOI: 10.1136/bmj.1.5854.655]
123 Sidi Y, Douer D, Pinkhas J. Simultaneous appearance of agranulo-
cytosis and cholestatic jaundice following chlorpromazine treat-
ment. Med Interne 1989; 27: 69-71 [PMID: 2749161]
124 Swett C. Adverse reactions to chlorpromazine in medical patients: 
a report from the Boston Collaborative Drug Surveillance Program, 
Boston University Medical Center. Curr Ther Res Clin Exp 1975; 
18: 199-206 [PMID: 809235]
125 Gaertner HJ, Fischer E, Hoss J. Side effects of clozapine. Psycho­
pharmacology (Berl) 1989; 99 Suppl: S97-100 [PMID: 2813671 DOI: 
10.1007/BF00442570]
126 Barrons E, Johnson E, Nynkowski P. Restarting clozapine: a case 
report. Psychiatr Serv 1996; 47: 92 [PMID: 8925356 DOI: 10.1176/
ps.47.1.92]
127 Bauer M. Concurrent agranulocytosis and acute hepatitis resulting 
from combination of classic neuroleptics and subsequent successful 
clozapine treatment. Pharmacopsychiatry 1995; 28: 29-31 [PMID: 
7746843 DOI: 10.1055/s-2007-979585]
128 Eggert AE, Crismon ML, Dorson PG, Taylor RL. Clozapine 
rechallenge after marked liver enzyme elevation. J Clin Psycho­
pharmacol 1994; 14: 425-426 [PMID: 7884025 DOI: 10.1097/000047
14-199412000-00010]
129 Erdogan A, Kocabasoglu N, Yalug I, Ozbay G, Senturk H. 
Management of marked liver enzyme increase during clozapine 
treatment: a case report and review of the literature. Int J Psychiatry 
Med 2004; 34: 83-89 [PMID: 15242144 DOI: 10.2190/44WA-WXF7-
3UHA-FDV1]
130 Fong SY, Au Yeung KL, Tosh JM, Wing YK. Clozapine-induced 
toxic hepatitis with skin rash. J Psychopharmacol 2005; 19: 107 
[PMID: 15671137 DOI: 10.1177/0269881105047287]
131 Keane S, Lane A, Larkin T, Clarke M. Management of clozapine-
related hepatotoxicity. J Clin Psychopharmacol 2009; 29: 606-607 
[PMID: 19910731 DOI: 10.1097/JCP.0b013e3181c163ef]
132 Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by 
clozapine treatment. Am J Psychiatry 1993; 150: 985-986 [PMID: 
8494085 DOI: 10.1176/ajp.150.6.985b]
133 Markowitz JS, Grinberg R, Jackson C. Marked liver enzyme 
elevations with clozapine. J Clin Psychopharmacol 1997; 17: 70-71 
[PMID: 9004073 DOI: 10.1097/00004714-199702000-00025]
134 Thatcher GW, Cates M, Bair B. Clozapine-induced toxic hepatitis. 
Am J Psychiatry 1995; 152: 296-297 [PMID: 7840371 DOI: 
10.1176/ajp.152.2.296b]
135 Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, 
24561328 DOI: 10.1097/JCP.0000000000000094]
93 Medicines and Healthcare products Regulatory Agency, Com-
mission on Human Medicines. Agomelatine (Valdoxan/Thymanax): 
risk of dose-related hepatotoxicity and liver failure - updated warnings 
and monitoring guidance. Drug Safety Update [Internet]. 2012; 6. 
Available from: URL: https://www.sussexpartnership.nhs.uk/sites/
default/files/documents/drug-safety-update-1012.pdf
94 Gruz F, Raffa S, Santucci C, Papale RM, Videla MG, Fernández 
MG, Yantorno S, Descalzi VI. Agomelatine: fulminant liver failure 
in a patient with fatty liver. Gastroenterol Hepatol 2014; 37: 92-94 
[PMID: 23849766 DOI: 10.1016/j.gastrohep.2013.04.008]
95 Montgomery SA. Safety of mirtazapine: a review. Int Clin 
Psychopharmacol 1995; 10 Suppl 4: 37-45 [PMID: 8930008 DOI: 
10.1097/00004850-199512004-00006]
96 Hui CK, Yuen MF, Wong WM, Lam SK, Lai CL. Mirtazapine-
induced hepatotoxicity. J Clin Gastroenterol 2002; 35: 270-271 
[PMID: 12192206 DOI: 10.1097/01.MCG.0000024793.18323.0B]
97 Bressolle F, Bres J, Blanchin MD, Gomeni R. Sulpiride pharma-
cokinetics in humans after intramuscular administration at three dose 
levels. J Pharm Sci 1984; 73: 1128-1136 [PMID: 6491918 DOI: 
10.1002/jps.2600730826]
98 Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical 
antipsychotics: involvement of cytochrome p450 enzymes and 
relevance for drug-drug interactions. Curr Drug Metab 2008; 9: 
410-418 [PMID: 18537577 DOI: 10.2174/138920008784746373]
99 Derby LE, Gutthann SP, Jick H, Dean AD. Liver disorders in patients 
receiving chlorpromazine or isoniazid. Pharmacotherapy 1993; 13: 
353-358 [PMID: 8361861 DOI: 10.1002/j.1875-9114.1993.tb02742.x]
100 Ahmed A. Hepatitis and phenothiazines. J Indian Med Assoc 1972; 
58: 300 [PMID: 4635961]
101 Bach N, Thung SN, Schaffner F, Tobias H. Exaggerated cholestasis 
and hepatic fibrosis following simultaneous administration of 
chlorpromazine and sodium valproate. Dig Dis Sci 1989; 34: 
1303-1307 [PMID: 2502367 DOI: 10.1007/BF01537284]
102 Walker CO, Combes B. Biliary cirrhosis induced by chlor-
promazine. Gastroenterology 1966; 51: 631-640 [PMID: 5926937]
103 Gruber LN, Chapman WW, Pratt-thomas HR. Fatal toxic reaction 
to chlorpromazine (Thorazine). Case report and brief review of 
literature. J S C Med Assoc 1963; 59: 203-204 [PMID: 13950880]
104 Rodin AE, Robertson DM. Fatal toxic hepatitis following 
chlorpromazine therapy; report of a case with autopsy findings. 
AMA Arch Pathol 1958; 66: 170-175 [PMID: 13558828]
105 Murphy JD, Ofner F. A case of chlorpromazine jaundice. Med J 
Aust 1956; 43: 504-505 [PMID: 13308597]
106 Boardman RH. Fatal case of toxic hepatitis implicating chlorpro-
mazine. Br Med J 1954; 2: 579 [PMID: 13182288 DOI: 10.1136/
bmj.2.4887.579]
107 Cammack KV, Hoffman JW, Dodds M. Thorazine jaundice. J 
Mich State Med Soc 1958; 57: 582-586 passim [PMID: 13539583]
108 Isaacs B, Macarthur JG, Taylor RM. Jaundice in relation to 
chlorpromazine therapy. Br Med J 1955; 2: 1122-1124 [PMID: 
13260678 DOI: 10.1136/bmj.2.4948.1122]
109 Elliott RN, Schrut AH, Marra JJ. Fatal acute aseptic necrosis of the 
liver associated with chlorpromazine. Am J Psychiatry 1956; 112: 
940 [PMID: 13313806 DOI: 10.1176/ajp.112.11.940]
110 Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver 
enzyme elevations with four different neuroleptics: a retrospective 
review of 7,263 treatment courses. J Clin Psychopharmacol 2001; 
21: 215-222 [PMID: 11270919 DOI: 10.1097/00004714-20010400
0-00014]
111 Fuller CM, Yassinger S, Donlon P, Imperato TJ, Ruebner B. 
Haloperidol-induced liver disease. West J Med 1977; 127: 515-518 
[PMID: 595591]
112 DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic 
syndrome in people with schizophrenia: a review. World Psychiatry 
2009; 8: 15-22 [PMID: 19293950 DOI: 10.1002/j.2051-5545.2009.
tb00199.x]
113 Taylor D, Patron C, Shitij K. Maudsley Prescribing Guidelines. 10 
ed. London, England: Informa Healthcare, 2009
114 Verma S, Kaplowitz N. Diagnosis, management and prevention 
Telles­Correia D et al . Psychotropic drugs and liver disease
37 February 6, 2017|Volume 8|Issue 1|WJGPT|www.wjgnet.com
154 Esposito D, Brocvielle H, Becquemont L, Hardy P, Chouinard G, 
Corruble E. Risperidone-induced immunoallergic hepatitis. Am J 
Psychiatry 2005; 162: 1984 [PMID: 16199856 DOI: 10.1176/appi.
ajp.162.10.1984]
155 Fuller MA, Simon MR, Freedman L. Risperidone-associated 
hepatotoxicity. J Clin Psychopharmacol 1996; 16: 84-85 [PMID: 
8834428 DOI: 10.1097/00004714-199602000-00018]
156 Krebs S, Dormann H, Muth-Selbach U, Hahn EG, Brune K, 
Schneider HT. Risperidone-induced cholestatic hepatitis. Eur J 
Gastroenterol Hepatol 2001; 13: 67-69 [PMID: 11204814 DOI: 
10.1097/00042737-200101000-00013]
157 Paulzen M, Orfanos S, Gründer G. Remission of drug-induced 
hepatitis after switching from risperidone to paliperidone. Am J 
Psychiatry 2010; 167: 351-352 [PMID: 20194492 DOI: 10.1176/
appi.ajp.2009.09081243]
158 Llinares Tello F, Hernández Prats C, Bosacoma Ros N, Pérez 
Martínez E, Climent Grana E, Navarro Polo JN, Ordovás Baines 
JP. Acute cholestatic hepatitis probably associated with risperidone. 
Int J Psychiatry Med 2005; 35: 199-205 [PMID: 16240976 DOI: 
10.2190/5XRB-D2XX-X8AH-32KB]
159 Whitworth AB, Liensberger D, Fleischhacker WW. Transient 
increase of liver enzymes induced by risperidone: two case reports. 
J Clin Psychopharmacol 1999; 19: 475-476 [PMID: 10505592 
DOI: 10.1097/00004714-199910000-00015]
160 Phillips EJ, Liu BA, Knowles SR. Rapid onset of risperidone-
induced hepatotoxicity. Ann Pharmacother 1998; 32: 843 [PMID: 
9681106 DOI: 10.1345/aph.18022]
161 López-Torres E, Süveges A, Peñas-LLedó EM, Doña A, Dorado 
P, LLerena A, Berecz R. Liver enzyme abnormalities during 
antipsychotic treatment: a case report of risperidone-associated 
hepatotoxicity. Drug Metabol Drug Interact 2014; 29: 123-126 
[PMID: 24598833 DOI: 10.1515/dmdi-2013-0064]
162 Oyewole D, Skerritt U, Montgomery S. Jaundice associated with 
the use of risperidone in a case of presenile dementia. Int J Geriatr 
Psychiatry 1996; 11: 177
163 Shpaner A, Li W, Ankoma-Sey V, Botero RC. Drug-induced liver 
injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol 
Hepatol 2008; 20: 1106-1109 [PMID: 19047843 DOI: 10.1097/
MEG.0b013e3282f8e3a0]
164 Al Mutairi F, Dwivedi G, Al Ameel T. Fulminant hepatic failure in 
association with quetiapine: a case report. J Med Case Rep 2012; 6: 
418 [PMID: 23234465 DOI: 10.1186/1752-1947-6-418]
165 El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure 
associated with quetiapine. Eur J Gastroenterol Hepatol 2004; 16: 
1415-1418 [PMID: 15618854 DOI: 10.1097/00042737-200412000-0
0029]
166 Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk 
H. Fatal hepatotoxicity in an elderly patient receiving low-dose 
quetiapine. Am J Psychiatry 2011; 168: 212-213 [PMID: 21297052 
DOI: 10.1176/appi.ajp.2010.10091292]
167 Tsai CF, Tsai SJ, Hwang JP. Ziprasidone-induced hypersensitivity 
syndrome in an aged schizophrenia patient. Int J Geriatr Psychiatry 
2005; 20: 797-799 [PMID: 16035110 DOI: 10.1002/gps.1346]
168 Shorvon SD. Handbook of Epilepsy Treatment. 3 ed. Hoboken, 
USA: Wiley-Blackwell, 2010
169 Dostert P, Benedetti S. Mécanismes biochimiques de l’hépatoxicité 
des psychotromes. L’ Encéphale 1984; 10: 199-209
170 Au JS, Pockros PJ. Drug-induced liver injury from antiepileptic 
drugs. Clin Liver Dis 2013; 17: 687-697, x [PMID: 24099025 DOI: 
10.1016/j.cld.2013.07.011]
171 Andrade RJ, Lucena MI, Alcantara R, Fraile JM. Bentazepam-
associated chronic liver disease. Lancet 1994; 343: 860 [PMID: 
7908109 DOI: 10.1016/S0140-6736(94)92065-6]
172 Fang MH, Ginsberg AL, Dobbins WO. Cholestatic jaundice 
associated with flurazepam hydrochloride. Ann Intern Med 1978; 
89: 363-364 [PMID: 28685 DOI: 10.7326/0003-4819-89-3-363]
173 Howrie DL, Zitelli BJ, J PM. Anticonvulsant-induced hepatotoxicity. 
Hosp Formul 1983; 18: 564-570
174 Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. 
Seizure 2006; 15: 156-164 [PMID: 16442314 DOI: 10.1016/
j.seizure.2005.12.009]
Bezner J, Schooler NR. Hepatitis, hyperglycemia, pleural effusion, 
eosinophilia, hematuria and proteinuria occurring early in clozapine 
treatment. Int Clin Psychopharmacol 1998; 13: 95-98 [PMID: 
9669191 DOI: 10.1097/00004850-199803000-00007]
136 Wirshing WC, Ames D, Bisheff S, Pierre JM, Mendoza A, Sun A. 
Hepatic encephalopathy associated with combined clozapine and 
divalproex sodium treatment. J Clin Psychopharmacol 1997; 17: 
120-121 [PMID: 10950478 DOI: 10.1097/00004714-199704000-00
013]
137 Worrall R, Wilson A, Cullen M. Dystonia and drug-induced 
hepatitis in a patient treated with clozapine. Am J Psychiatry 1995; 
152: 647-648 [PMID: 7694924 DOI: 10.1176/ajp.152.4.647b]
138 Panagiotis B. Grand mal seizures with liver toxicity in a case of 
clozapine treatment. J Neuropsychiatry Clin Neurosci 1999; 11: 
117-118 [PMID: 9990571 DOI: 10.1176/jnp.11.1.117a]
139 Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report 
of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 
2001; 321: 156-158 [PMID: 11217818 DOI: 10.1097/00000441-20
0102000-00008]
140 Contoreggi C, Cheskin LJ, Lange WR. Acute hepatitis after 
clozapine administration: a case report and review. Am J Addict 
1996; 5: 5Y11 [DOI: 10.3109/10550499608995650]
141 Chang A, Krygier DS, Chatur N, Yoshida EM. Clozapine-induced 
fatal fulminant hepatic failure: a case report. Can J Gastroenterol 
2009; 23: 376-378 [PMID: 19440569 DOI: 10.1007/978-3-540-85705
-1_38]
142 Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley 
J. Fatal acute fulminant liver failure due to clozapine: a case report 
and review of clozapine-induced hepatotoxicity. Gastroenterology 
1997; 112 :  1707-1709 [PMID: 9136851 DOI: 10.1016/
S0016-5085(97)70054-4]
143 Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, 
Ustundag Y. A review of liver function tests during treatment with 
atypical antipsychotic drugs: a chart review study. Prog Neuropsy­
chopharmacol Biol Psychiatry 2007; 31: 1255-1260 [PMID: 
17600607 DOI: 10.1016/j.pnpbp.2007.05.005]
144 Hung CC, Wei IH, Huang CC. Late-onset cholestatic hepatitis 
induced by olanzapine in a patient with schizophrenia. Prog 
Neuropsychopharmacol Biol Psychiatry 2009; 33: 1574-1575 
[PMID: 19766687 DOI: 10.1016/j.pnpbp.2009.09.011]
145 Jadallah KA, Limauro DL, Colatrella AM. Acute hepatocellular-
cholestatic liver injury after olanzapine therapy. Ann Intern Med 
2003; 138: 357-358 [PMID: 12585842 DOI: 10.7326/0003-4819-13
8-4-200302180-00023]
146 Lui SY, Tso S, Lam M, Cheung EF. Possible olanzapine-induced 
hepatotoxicity in a young Chinese patient. Hong Kong Med J 2009; 
15: 394-396 [PMID: 19801701]
147 Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat 
K, Sonsuz A. Severe liver enzyme elevations after three years of 
olanzapine treatment: a case report and review of olanzapine associated 
hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 2006; 
30: 1163-1166 [PMID: 16632162 DOI: 10.1016/j.pnpbp.2006.03.014]
148 Tchernichovsky E, Sirota P. Hepatotoxicity, leucopenia and 
neutropenia associated with olanzapine therapy. Int J Psychiatry Clin 
Pract 2004; 8: 173-177 [PMID: 24941207 DOI: 10.1080/1365150041
0005577]
149 Waage C, Carlsson H, Nielsen EW. Olanzapine-induced pancreatitis: 
a case report. JOP 2004; 5: 388-391 [PMID: 15365209]
150 Pae CU, Lim HK, Kim TS, Kim JJ, Lee CU, Lee SJ, Lee C, Paik 
IH. Naturalistic observation on the hepatic enzyme changes in 
patients treated with either risperidone or olanzapine alone. Int 
Clin Psychopharmacol 2005; 20: 173-176 [PMID: 15812269 DOI: 
10.1097/00004850-200505000-00009]
151 Wright TM, Vandenberg AM. Risperidone- and quetiapine-induced 
cholestasis. Ann Pharmacother 2007; 41: 1518-1523
152 Benazzi F. Risperidone-induced hepatotoxicity. Pharmacopsychia­
try 1998; 31: 241 [PMID: 9930641 DOI: 10.1055/s-2007-979337]
153 Cordeiro Q, Elkis H. Pancreatitis and cholestatic hepatitis induced 
by risperidone. J Clin Psychopharmacol 2001; 21: 529-530 [PMID: 
11593080 DOI: 10.1097/00004714-200110000-00012]
Telles­Correia D et al . Psychotropic drugs and liver disease
38 February 6, 2017|Volume 8|Issue 1|WJGPT|www.wjgnet.com
176 Andrade RJ, Lucena MI, Fernández MC, Vega JL, Camargo R. 
Hepatotoxicity in patients with cirrhosis, an often unrecognized 
problem: lessons from a fatal case related to amoxicillin/clavulanic 
acid. Dig Dis Sci 2001; 46: 1416-1419 [PMID: 11478492]
177 Golebiewski K. Antipsychotic Monitoring. Graylands Hosp Drug 
Bull 2006; 14: 4
P- Reviewer: Milovanovic JR    S- Editor: Song XX 
L- Editor: A    E- Editor: Wu HL
175 Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-
Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN. Comparative 
benefits and harms of second-generation antidepressants: 
background paper for the American College of Physicians. Ann 
Intern Med 2008; 149: 734-750 [PMID: 19017592 DOI: 10.7326/0
003-4819-155-11-201112060-00009]
Telles­Correia D et al . Psychotropic drugs and liver disease
                                      © 2017 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
